GlassScriptPhysician profile
Ayman Fakeh
NPI 1245469345
$2,368.40
in general payments reported to CMS, 2019-2025
21 companies · $661 in 2025
The $661 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $102 · 2022: $164 · 2023: $202 · 2024: $916 · 2025: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,779.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $422.45 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $369.65 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $297.07 | 2022-2025 | |
| Exact Sciences Corporation | $188.27 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $153.37 | 2019-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $152.89 | 2019-2024 | Bexsero, Shingrix, Arexvy |
| Abbott Laboratories | $151.69 | 2024 | Freestyle Libre 3 |
| Pfizer INC. | $129.71 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $85.58 | 2019-2025 | |
| Astellas Pharma US INC | $69.74 | 2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $69.42 | 2024 | Airsupra, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.45 | 2024-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $50.26 | 2019-2025 | |
| Medtronic, INC. | $37.42 | 2025 | Symplicity G3 |
| Hologic Sales and Service, LLC | $24.82 | 2024 | Aptima, Thinprep 2000 Processor |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $23.90 | 2025 | Voquezna |
| Phadia US INC. | $18.15 | 2023 | Immunocap |
| Shield Therapeutics INC | $15.93 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2019 | |
| Medtronic Minimed, INC. | $13.93 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayman Fakeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.